Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics
Ed olimpio2022-01-17T20:26:32+00:00Dr, Stephen Byrn, CSO of Improved Pharma, was a key contributor to a recent publication describing the usefulness of mini-tablets in monitoring the dose-response of lapatinib solid amorphous dispersions in juvenile pigs. Juvenile pigs have been well-established Read more